E mutation at Codon 581. PLoS 1 2009, 4:e4569. Raman J, Mauff K
E mutation at Codon 581. PLoS 1 2009, 4:e4569. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI: 5 years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS 1 2011, six:e25992. Polski JM, Kimzey S, Percival RW, Grosso LE: Fast and successful processing of blood specimens for diagnostic PCR utilizing filter paper and Chelex-100. Mol Pathol 1998, 51:21517. Jelinek T, Ronn AM, Curtis J, Duraisingh MT, Lemnge MM, Mhina J, Bygbjerg IC, Warhurst DC: Higher prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without the need of proof of an association to clinical sulfadoxine/ pyrimethamine resistance. Trop Med Int Wellness 1997, 2:1075079. University of Mayland College of Medicine: PCR-allele-specific restriction evaluation (ASRA): protocols for Plasmodium falciparum drug resistance mutation analyses. University of Mayland; 2002. Accessed:10-5-2013. Schonfeld M, Barreto MI, Schunk M, Maduhu I, Maboko L, Hoelscher M, Berens-Riha N, Kitua A, Loscher T: Molecular surveillance of drug-resistance related mutations of Plasmodium falciparum in south-west Tanzania. Malar J 2007, six:two. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G: Efficacy of artemether-lumefantrine in therapy of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Malar J 2012, 11:58. Minja DT, Schmiegelow C, Mmbando B, Bostrom S, Oesterholt M, Magistrado P, Pehrson C, John D, Salanti A, Luty AJ, Lemnge M, Theander T, Lusingu J, Alifrangis M: Plasmodium falciparum mutant haplotype infection22.23.24.25.26.27.28.29.30.31.32.33.34. 35.36.throughout pregnancy associated with lowered birthweight, Tanzania. Emerg Infect Dis 2013, 19: doi: ten.3201. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC: Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation inside the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg 2009, 80:52327. Malisa AL, Pearce RJ, Mutayoba BM, Abdullah S, Mshinda H, Kachur PS, Bloland P, Roper C: The CDK9 Inhibitor Formulation evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection below SP alone vs SP + artesunate combination. Malar J 2011, 10:317. Pearce RJ, Ord R, Kaur H, Lupala C, Schellenberg J, Shirima K, Manzi F, Alonso P, Tanner M, Mshinda H, Roper C, Schellenberg D: A communityrandomized evaluation with the effect of intermittent preventive therapy in infants on antimalarial drug resistance in southern Tanzania. J Infect Dis 2013, 207:84859. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, Vanden EJ, Owino SO, Lal AA, CB1 Agonist review Omosun YO, Otieno K, Desai M, ter Kuile FO, Nahlen B, Moore J, Hamel MJ, Ouma P, Slutsker L, Shi YP: Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant ladies in western Kenya. Malar J 2012, 11:134. Raman J, Small F, Roper C, Kleinschmidt I, Cassam Y, Maharaj R, Barnes KI: 5 years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg 2010, 82:78894. Doumbo S, Ongoiba OA,.